Ixabepilone

Mani, Sridhar; Ghalib, Mohammad H.; Goel, Sanjay; Serradell, N.; Bolós, J.; Rosa, E.

doi:10.1358/dof.2007.032.12.1157611

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, ixabepilone, a semisynthetic analogue of the natural product epothilone B, produced by the myxobacterium Sorangium cellulosum (order Myxococcales), acts as microtubulestabilizing agent and was approved in 2007 by the Food and Drug Administration of the USA (FDA) for the treatment of metastatic breast cancer ( Fig. 1; Conlin et al 2007;Mani et al 2007). …”

Section: Introductionmentioning

confidence: 99%

Fungal metabolites: structural diversity as incentive for anticancer drug development

et al. 2010

View full text Add to dashboard Cite

Natural products play an important role in the development of anticancer drugs. To date, predominantly metabolites from plants and bacteria served as lead structures for anticancer agents. Fungal metabolites and derivatives thereof are much less investigated for their potential in cancer therapy. There are, however, some promising candidates derived from fungi in clinical phases I and II studies. This review gives an overview on the role of natural products in cancer therapy and summarises some of the latest results of our group in this area.

show abstract

Section: Introductionmentioning

confidence: 99%

Fungal metabolites: structural diversity as incentive for anticancer drug development

et al. 2010

View full text Add to dashboard Cite

show abstract

The exploration of macrocycles for drug discovery — an underexploited structural class

Driggers

Hale

Lee

et al. 2008

Nat Rev Drug Discov

1,216

1,133

View full text Add to dashboard Cite

Macrocyclic natural products have evolved to fulfil numerous biochemical functions, and their profound pharmacological properties have led to their development as drugs. A macrocycle provides diverse functionality and stereochemical complexity in a conformationally pre-organized ring structure. This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations. Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery. This is in part due to concerns about synthetic intractability and non-drug-like properties. This Review describes the growing body of data in favour of macrocyclic therapeutics, and demonstrates that this class of compounds can be both fully drug-like in its properties and readily prepared owing to recent advances in synthetic medicinal chemistry.

show abstract

From Rings to Remedies: Investigating the Structure-Activity Relationship of Macrocyclic Anticancer Agents

Rani,

Aslam,

Irfan

et al. 2024

Heterocyclic Chemistry - New Perspectives [Working Title]

View full text Add to dashboard Cite

The profound pharmacological attributes of macrocyclic compounds have spurred their transformation into pharmaceutical drugs. Within conformationally pre-organized ring structures, the macrocycle’s intricate functions and stereochemical complexity contribute to a heightened affinity and selectivity for protein targets. Simultaneously, they maintain sufficient bioavailability to penetrate intracellular locations. As a result, the construction of macrocycles emerges as an optimal strategy for addressing the challenge of “undruggable” targets like cancer. Cancer stands as the second most prevalent and formidable threat to human life, prompting researchers to channel their efforts toward the extraction and synthesis of effective therapeutic drugs designed on macrocyles to combat various types of cancer cells. Many macrocyclic drugs have been licensed by the Food and Drug Administration (FDA) for the treatment of cancer patients. Nonetheless, the significance of these compounds in the production of cancer therapeutics is still undervalued. According to recent research, macrocyclic compounds can be a useful tactic in the fight against drug resistance in the treatment of cancer. This chapter aims to present bits of evidence about the uses of macrocyclic compounds as potential cancer treatments. By providing more innovative approaches to aid cancer patients and society as a whole, this chapter will hopefully stimulate greater interest in the development of macrocyclic medicines for cancer therapy.

show abstract

Ixabepilone

Cited by 3 publications

References 0 publications

Fungal metabolites: structural diversity as incentive for anticancer drug development

Fungal metabolites: structural diversity as incentive for anticancer drug development

The exploration of macrocycles for drug discovery — an underexploited structural class

From Rings to Remedies: Investigating the Structure-Activity Relationship of Macrocyclic Anticancer Agents

Contact Info

Product

Resources

About